Clinical trials: Dry Eye
Eyes Dry Chronic
ESBA105 in Patients With Severe Dry Eye
The purpose of this study was to evaluate the efficacy of ESBA105 over vehicle in reducing the ocular symptoms of dry eye disease, as measured by a mean global Visual Analog Scale (VAS) discomfort score.
- Trial name
- NCT01338610
- Testing
- ESBA105 ophthalmic solution, ESBA105 vehicle
- Where
- United States
- Volunteers
- 334 people
- Sponsor
- Alcon Research
Meibomian Gland Dysfunction, Evaporative Dry Eye
Tear Film Innovations iLux Safety Study
The objective of this study was to measure the temperature of the cornea and surrounding eye tissue temperature immediately after heating the eyelids with the iLux device using the protocol treatment profile.
- Trial name
- NCT03055897
- Testing
- iLux 2020 System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Tear Film Innovations, Inc.
Dry Eye Disease
Study of ST-100 as Treatment for Dry Eye Disease
The objective of this study is to compare the safety and efficacy of two different concentrations of ST-100 Ophthalmic Solution to placebo (vehicle) for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT05241470
- Testing
- ST-100 Ophthalmic Solution
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Stuart Therapeutics, Inc.
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
A Multi-Center, Phase 2/3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Voclosporin Ophthalmic Solution (0.05%, 0.10%, 0.20%) Compared to Vehicle in Subjects…
- Trial name
- AUDREY (NCT04147650)
- Testing
- 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS
- Where
- 9 sites in United States
- Volunteers
- 508 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Dry Eye
A Clinical Trial to Assess Subjects With Dry Eye Disease.
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
- Trial name
- NCT04971031
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dry Eye Syndromes, Sjogren's Syndrome
TrueTear in Sjogren's Disease Patients
The purpose of this study is to evaluate acute tear production produced by the intranasal tear neurostimulator in participants with Sjögrens syndrome and aqueous tear deficiency.
- Trial name
- NCT03719885
- Testing
- TrueTear Intranasal Tear Neurostimulator
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Dry Eye Disease
Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%
The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who…
- Trial name
- NCT00827255
- Testing
- Cyclosporine Ophthalmic Emulsion 0.05%
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Allergan
Dry Eye Syndromes
Efficacy and Acceptability of Two Lubricant Eye Drops
Efficacy and acceptability of two new artificial tears following two weeks of treatment in patients with dry eye. Patients will be randomized to 1 of 2 treatments for 7 days then crossover to the alternate treatment for 7 days.
- Trial name
- NCT00756678
- Testing
- Lubricant Eye Drops (Optive™), Lubricating Eye Drops (blink® Tears)
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Allergan
Geographic Atrophy, Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)
This study was conducted in two parts; Part A and Part B: Part B was initially planned to include two cohorts. Cohort 2 was cancelled following an interim analysis for efficacy in Part A of the study, and not due to any safety…
- Trial name
- NCT01527500
- Testing
- LFG316, LFG316 Lower dose
- Where
- 19 sites in United States
- Volunteers
- 158 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye
Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)
SDP-4-CS202 is a Phase 2, multicenter, double-masked, randomized, vehicle-controlled, parallel group study designed to evaluate the ocular efficacy of SDP-4 ophthalmic solution in subjects with moderate to severe dry eye disease…
- Trial name
- NCT04535947
- Testing
- Vehicle, SDP-4 Ophthalmic Solution (1.0%)
- Where
- 5 sites in United States
- Volunteers
- 153 people
- Sponsor
- Silk Technologies, Ltd.
Dry Eye Disease
Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease
The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.
- Trial name
- NCT02831387
- Testing
- P-321 Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Parion Sciences
Dry Eye
Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease
Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).
- Trial name
- NCT03597139
- Testing
- Voclosporin Ophthalmic Solution, Restasis®
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Syndrome
Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome
The aim of the current study is to examine the contribution of intense pulsed light (IPL) for relieving signs and symptoms of dry eye due to meibomian gland dysfunction.
- Trial name
- NCT03396913
- Testing
- IPL, MGX
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Lumenis Be Ltd.
Dry Eye
LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
The purpose of this study is to evaluate the efficacy of LME636 compared to vehicle in the reduction of ocular symptoms and to evaluate the safety and tolerability of LME636, when administered topically for up to 42 days, in…
- Trial name
- NCT02365519
- Testing
- LME636 ophthalmic solution, LME636 Vehicle
- Volunteers
- 514 people
- Sponsor
- Alcon, a Novartis Company
Age-Related Macular Degeneration
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells.
- Trial name
- NCT02286089
- Testing
- OpRegen
- Where
- 7 sites in United States, Israel
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Dry Eye Disease
A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
Evaluate the efficacy and safety of Lifitegrast in subjects with dry eye disease and a recent history of artificial tear use.
- Trial name
- OPUS-3 (NCT02284516)
- Testing
- Lifitegrast
- Where
- 41 sites in United States
- Volunteers
- 711 people
- Sponsor
- Shire
Keratoconjunctivitis Sicca
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
This study is being conducted to investigate the safety, comfort, and tolerability of 3 treatments: loteprednol etabonate ophthalmic (Lotemax®) gel 0.5 percent (%) administered twice daily (BID) with or without cyclosporine…
- Trial name
- NCT01817582
- Testing
- Lotemax, Restasis, Soothe® Lubricant Eye Drops
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Syndrome
Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Comparison of the efficacy and safety of T2762 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome
- Trial name
- NCT02023268
- Testing
- T2762, Vismed®
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Laboratoires Thea